BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hypothalamus
,
Amniocentesis
,
Doxorubicin
,
rs7903146
,
IGF1
,
Angiogenesis
,
Influenza
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
α5β1 integrins
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for α5β1 integrins
Explore Curated Studies Results
Literature
Most Relevant Literature
Force-Regulated Spontaneous Conformational Changes of Integrins α5β1 and αVβ3.
Unraveling the molecular basis for effective regulation of integrin α5β1 for enhanced therapeutic in…
Integrin A5B1-mediated endocytosis of polystyrene nanoplastics: Implications for human lung disease …
Regulation of integrin α5β1-mediated Staphylococcus aureus cellular invasion by the septin cytoskele…
Implication of integrin α5β1 in senescence of SK-Mel-147 human melanoma cells.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated Wit…
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Adva…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ